sever
acut
respiratori
syndrom
sar
seriou
type
pneumonia
first
recogn
late
subsequ
shown
caus
sar
coronaviru
scv
scv
genom
sequenc
within
week
initi
identif
analysi
reveal
scv
close
relat
group
coronavirus
scvlike
virus
known
varieti
anim
reservoir
includ
palm
civet
raccoon
dog
horsesho
bat
scv
also
abl
infect
cat
warn
possibl
transmiss
rout
viru
surveil
infectioncontrol
measur
success
contain
scv
treatment
possibl
viru
reemerg
effect
vaccin
develop
scv
protein
main
proteinas
cystein
proteinas
nucleosid
triphosph
hydrolas
ntpase
helicas
rna
polymeras
protein
identifi
potenti
target
antivir
therapi
alreadi
undergon
preliminari
character
previous
overexpress
biochem
character
scv
ntpasehelicas
protein
found
belong
distinct
class
viral
helicas
analog
close
relat
helicas
human
coronaviru
also
shown
scv
ntpasehelicas
rna
cap
activ
abl
unwind
rna
dna
duplex
helicas
previous
identifi
attract
target
antivir
drug
design
previous
identifi
scv
helicas
inhibitor
inhibit
viru
cell
cultur
divers
librari
compound
furthermor
character
bananin
class
compound
inhibit
helicas
viru
cell
cultur
cysteinerich
metal
bind
domain
mbd
locat
n
terminu
scv
helicas
protein
analog
mbd
close
relat
arteriviru
helicas
shown
involv
subgenom
mrna
synthesi
genom
replic
virion
biogenesi
previous
shown
unusu
strong
cysteinebismuth
interact
metallothionein
test
hypothesi
bismuth
ion
might
bind
within
mbd
therebi
affect
enzymat
activ
helicas
initi
set
assay
test
bismuth
compound
abil
inhibit
oligonucleotid
oligo
dt
stimul
atpas
atp
adenosin
activ
scv
ntpasehelicas
figur
phosphat
releas
owe
atp
hydrolysi
measur
variou
concentr
potenti
inhibitor
express
percentag
atpas
rate
absenc
inhibitor
see
support
inform
primari
screen
reveal
bismuthbas
compound
effect
inhibitor
scv
helicas
bismuth
nitrilotriacet
bi
nta
bismuth
nitrat
bi
nit
bismuth
tricystein
complex
bi
cy
ranitidin
bismuth
citrat
rbc
appear
efficaci
inhibitor
atpas
activ
show
signific
inhibit
concentr
mm
figur
similar
inhibitori
potenti
three
compound
suggest
bismuth
ion
play
key
role
inhibitori
effect
bismuth
ethylenediaminetetraacet
bi
edta
surprisingli
poor
inhibitor
indic
complex
group
bind
bismuth
bi
tightli
owe
clinic
use
rbc
chose
compound
studi
investig
whether
rbc
specif
inhibit
rnaor
dnastimul
basal
atpas
activ
helicas
perform
three
ident
set
experi
presenc
olig
rna
mimic
presenc
oligo
dt
dna
mimic
absenc
oligonucleotid
shown
figur
b
rbc
inhibit
dnaand
rnastimul
well
nonstimul
atpas
activ
helicas
similar
extent
ic
valu
calcul
fit
logist
equat
rbc
inhibit
dataset
ic
nm
u
stimul
atpas
dt
stimul
atpas
nonstimul
atpas
establish
rbc
could
effect
inhibit
atpas
activ
helicas
next
investig
whether
could
also
inhibit
duplexunwind
activ
use
previous
develop
radioassay
see
support
inform
measur
inhibit
helicas
abil
separ
two
strand
small
dna
molecul
compris
short
oligonucleotid
label
po
end
figur
ss
releas
strand
anneal
complementari
longer
strand
gener
partial
duplex
figur
ds
poli
dt
overhang
duplex
separ
experi
perform
rang
rbc
concentr
observ
duplex
almost
fulli
unwound
absenc
rbc
figur
lane
howev
activ
significantli
inhibit
presenc
mm
rbc
figur
lane
b
higher
concentr
rbc
unwind
activ
almost
total
inhibit
mm
rbc
figur
lane
c
e
respect
data
set
indic
helicas
ic
rang
mm
verifi
dnaunwind
inhibit
result
obtain
precis
ic
valu
use
helicas
assay
base
fluoresc
reson
energi
transfer
fret
fluorophor
quencher
black
hole
quencher
previous
describ
use
differ
helicas
see
support
inform
alter
partial
dnaduplex
substrat
molecul
make
compat
polar
scv
helicas
conduct
reaction
fluorimetr
cuvett
scv
helicas
first
allow
equilibr
duplex
indic
rbc
appropri
concentr
use
buffer
system
atpas
assay
reaction
initi
addit
adenosin
atp
mm
increas
fluoresc
l
ex
nm
l
em
nm
owe
releas
strand
measur
one
minut
determin
extent
reaction
data
collect
fit
logist
equat
figur
b
helicas
ic
valu
mm
good
agreement
radiolabel
assay
helicas
activ
discuss
earlier
bi
ion
known
high
affin
thiolat
sulfur
therefor
measur
uv
absorb
spectrum
scv
helicas
absenc
presenc
mm
rbc
figur
addit
rbc
broad
shoulder
differ
spectra
observ
wavelength
nm
characterist
format
bi
bond
shoulder
similar
profil
report
bismuth
bind
cystein
residu
metallothionein
bind
event
appear
fairli
rapid
greater
complet
within
two
minut
addit
rbc
slight
increas
absorpt
observ
follow
two
hour
unlik
bind
bismuth
metallothionein
transferrin
proceed
sever
hour
like
bind
zn
ion
scv
helicas
mbd
essenti
enzymat
activ
therefor
clone
express
purifi
mbd
scv
studi
biophys
properti
isol
see
support
inform
zn
bound
mbd
retent
time
min
determin
gel
filtrat
chromatographi
superdex
gl
correspond
molecular
weight
kda
see
figur
support
inform
indic
zn
mbd
trimer
solut
stoichiometri
zn
ion
bind
mbd
measur
use
zinc
chelat
resorcinol
par
togeth
thiolmodifi
reagent
phydroxymercuriphenylsulfon
acid
pmp
absorb
zn
par
approxim
nm
increas
gradual
addit
pmp
buffer
solut
mbd
par
figur
b
zinc
concentr
calcul
use
zn
par
standard
curv
reveal
total
zinc
concentr
time
mbd
indic
three
zn
ion
bind
mbd
monom
figur
perform
similar
titrat
experi
measur
ratio
bi
ion
bind
mbd
new
absorb
peak
appear
approxim
nm
uvvi
spectrum
mbd
increas
intens
almost
linearli
approxim
mol
equival
upon
gradual
addit
bi
ion
signific
increas
absorpt
observ
upon
addit
bi
ion
suggest
mbd
monom
also
bind
bi
ion
figur
c
bi
ion
effect
compet
zn
ion
bind
site
taken
combin
enzymat
data
suggest
bi
ion
bind
strongli
metal
bind
domain
helicas
therebi
disrupt
inhibit
ntpase
helicas
activ
may
note
point
mutat
within
mbd
helicas
close
relat
equin
arter
visu
eav
led
sever
defici
viral
replic
infect
cell
cultur
investig
inhibitori
properti
rbc
assess
antiscv
activ
clinic
isol
scv
strain
cell
initi
experi
examin
cytopathogen
effect
phasecontrast
microscopi
h
infect
viru
see
support
inform
shown
figur
uninfect
cell
appear
smooth
whilst
infect
cell
show
promin
ridgelik
structur
along
membran
structur
less
promin
treatment
mm
rbc
effect
difficult
quantifi
eye
confirm
result
use
viral
viabil
assay
measur
effect
rbc
treatment
measur
viral
reproduct
presenc
rbc
use
tcid
protocol
determin
number
viabl
viru
particl
cellcultur
supernat
h
postscv
infect
see
support
inform
rbc
significantli
inhibit
scv
reproduct
viral
titer
reduc
approxim
mm
concentr
mm
rbc
almost
complet
inhibit
scv
infect
replic
andor
releas
data
fit
logist
equat
give
effect
concentr
ec
valu
mm
viabl
scv
express
use
logarithm
scale
cell
viabil
figur
b
effect
concentr
ec
valu
mm
obtain
measur
cytotox
rbc
cell
cultur
use
standard
bromid
mtt
assay
base
reduct
mtt
tetrazolium
salt
formazan
dye
reaction
catalyz
mitochondri
succin
dehydrogenas
present
metabol
activ
cell
see
support
inform
growth
rate
rbctreat
untreat
cell
also
compar
mushroom
toxin
aamanitin
use
posit
control
fit
data
logist
equat
yield
cytotox
concentr
cc
mm
figur
c
ec
rbc
inhibit
scv
measur
mm
result
reveal
specif
constant
cc
ec
indic
rbc
act
effect
specif
manner
monkeykidney
cellcultur
system
attempt
delin
mechan
rbcmediat
inhibit
viral
replic
kinet
scv
infect
presenc
rbc
determin
quantit
realtim
pcr
qrtpcr
use
monitor
rel
quantiti
viral
rna
specifi
primer
scv
spike
gene
cellular
rna
specifi
primer
housekeep
gene
bactin
see
support
inform
found
h
infect
rbc
littl
effect
rel
quantiti
viral
rna
figur
time
even
high
concentr
rbc
mm
unabl
reduc
viral
rna
level
rel
control
absenc
drug
howev
h
rbc
greater
effect
mm
rbc
caus
reduct
viral
rna
level
h
concentr
mm
rbc
caus
approxim
reduct
viral
rna
level
data
therefor
suggest
rbc
play
greater
inhibitori
role
later
stage
replic
cycl
scv
helicas
act
later
stage
cycl
would
consist
rbc
inhibit
scv
helicas
function
within
cell
distinct
benefit
develop
bismuthbas
compound
therapeut
intervent
mani
drug
rbc
alreadi
use
clinic
treat
disord
within
alimentari
tract
particularli
relev
case
scv
previous
found
present
faec
sar
patient
possibl
import
rout
viral
transmiss
moreov
symptom
diarrhea
observ
hospit
patient
confirm
sar
infect
bismuth
compound
could
test
scv
prophylact
role
part
combin
therapi
treatment
infect
caus
nidovirus
summari
test
sever
bismuth
complex
potenti
inhibitor
scv
helicas
protein
rbc
found
particularli
strong
inhibitor
atpas
activ
scv
helicas
protein
ic
valu
mm
fretbas
assay
show
rbc
inhibit
dna
duplex
unwind
activ
ic
valu
mm
uvvi
data
confirm
bismuth
bind
cystein
residu
helicas
protein
analog
bind
behavior
toward
ntermin
metal
bind
domain
indic
bismuth
bind
cysteinerich
region
cell
cultur
rbc
effect
inhibit
scv
reproduct
ec
valu
mm
exhibit
moder
low
cytotox
cc
valu
mm
qrtpcr
experi
indic
rbc
inhibit
latestag
process
scv
replic
cycl
consist
helicas
target
drug
within
cell
take
consider
propos
mechan
action
high
select
present
clinic
usag
suggest
bismuthbas
drug
evalu
treatment
scv
infect
vivo
bismuth
citrat
bi
cit
bi
nta
bi
cy
bi
edta
bismuth
acetohydroxam
bi
aha
complex
prepar
mix
bismuth
salt
appropri
amount
ligand
eg
acetohydroxam
aha
describ
previous
ranitidin
bismuth
citrat
provid
glaxowellcom
china
ltd
helicas
prepar
mm
trishcl
ml
ph
tri
tri
hydroxymethyl
aminomethan
mm
nacl
concentr
mg
ml
rbc
ad
final
concentr
mm
appropri
delay
minut
allow
bind
measur
uvvi
spectrum
mbd
prepar
mm
trishcl
ph
mm
nacl
zn
ion
titrat
experi
mm
pmp
ad
gradual
mixtur
mm
mbd
mm
par
ml
mbdpar
uv
vi
cuvett
absorb
nm
record
zn
par
standard
curv
construct
measur
uvvi
absorb
nm
mm
par
variou
dilut
zinc
atom
absorpt
standard
solut
bi
ion
titrat
experi
mm
bi
nta
gradual
ad
mm
mbd
mm
trishcl
ph
mm
nacl
solut
total
volum
ml
final
concentr
mm
mol
equival
mbd
bind
bi
ion
mbd
examin
uvvi
spectroscopi
monitor
chang
absorpt
approxim
nm
receiv
march
revis
june
publish
onlin
juli
keyword
antivir
agent
bismuth
enzym
helic
structur
sar
coronaviru
